Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06717438
PHASE2

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

Sponsor: Shionogi

View on ClinicalTrials.gov

Summary

The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.

Official title: A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)

Key Details

Gender

All

Age Range

9 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-05-13

Completion Date

2030-01-31

Last Updated

2026-01-20

Healthy Volunteers

No

Interventions

DRUG

BPN14770

Capsules for oral administration

DRUG

Placebo

Capsules for oral administration

Locations (3)

Rush University Medical Center

Chicago, Illinois, United States

Boston Children's Hospital

Boston, Massachusetts, United States

Seattle Children's Hospital

Seattle, Washington, United States